Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), was shown to be active in colorectal cancer. Although some patients who harbor K-ras wild-type tumors benefit from cetuximab treatment, 40 to 60% of patients with wild-type K-ras tumors do not respond to cetuximab. Currently, there is no universal marker or method of clinical utility that could guide the treatment of cetuximab in colorectal cancer. Here, we demonstrate a method to predict response to cetuximab in patients with colorectal cancer using OncoFinder pathway activation strength (PAS), based on the transcriptomic data of the tumors. We first evaluated our OncoFinder pathway activation strength model in a set of transcriptomic data obtained from patient-derived xenograft (PDx) models established from colorectal cancer biopsies. Then, the approach and models were validated using a clinical trial data set. PAS could efficiently predict patients’ response to cetuximab, and thus holds promise as a selection criterion for cetuximab treatment in metastatic colorectal cancer. The gene expression profile of a patient’s colorectal tumor can help doctors predict how they will respond to therapy using the drug cetuximab. Colorectal cancer patients without a mutation on a gene called K--ras have the potential to respond well to cetuximab treatment, but up to 60% of such patients do not. A research team led by David Sidransky from Johns Hopkins University School of Medicine in the USA used a bioinformatic program called OncoFinder to analyze the genes activated in colorectal tumor tissue taken from patients and patient-derived mice models to identify a prognostic marker for cetuximab treatment. For both the mouse model and retrospective clinical data, the OncoFinder PAS correlated well with the sensitivity of tumors to cetuximab, providing a promising selection criterion for cetuximab treatment in metastatic colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
Zhu, C.-Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.-C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8924 · Cited by 661
Jhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460
Pentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Xanthakis, I., Sgouros, J., Televantou, D., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-49 · Cited by 111
Poindessous, V., Ouaret, D., El Ouadrani, K., Battistella, A., Mégalophonos, V. F., Kamsu-Kom, N., Petitprez, A., Escargueil, A. E., Boudou, P., Dumont, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1607 · Cited by 55
Cited by
Aliper, A., Plis, S., Artemov, A., Ulloa, A., Mamoshina, P., & Zhavoronkov, A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00248 · Cited by 610
Self-citationMamoshina, P., Ojomoko, L., Yanovich, Y., Ostrovski, A., Botezatu, A., Prikhodko, P., Izumchenko, E., Aliper, A., Romantsov, K., Zhebrak, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.22345 · Cited by 471
“…medicine in oncology and other diseases relied on the various data types including the multiple types of genomic [6–10], transcriptomic [11–13], microRNA [14], proteomic [15], antigen [16], methylation [17], imaging [18, 19], metagenomic [20], mitochondrial [21], metabolic [22],…”
BackgroundSelf-citationKadurin, A., Aliper, A., Kazennov, A., Mamoshina, P., Vanhaelen, Q., Khrabrov, K., & Zhavoronkov, A. (2017) · Oncotarget · doi:10.18632/oncotarget.14073 · Cited by 350
Self-citationPun, F. W., Liu, B. H. M., Long, X., Leung, H. W., Leung, G. H. D., Mewborne, Q. T., Gao, J., Shneyderman, A., Ozerov, I. V., Wang, J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.914017 · Cited by 115
“According to a pooled summary of mutation frequency in 111 studies, those four major ALS-associated genes explain 47.7% fALS and 5.2% sporadic ALS (sALS) cases (Zou et al., 2017), leaving a substantial fraction of the genetic basis of ALS undiscovered.”
BackgroundInfluentialSelf-citationKamashev, D., Shaban, N., Lebedev, T., Prassolov, V., Suntsova, M., Raevskiy, M., Gaifullin, N., Sekacheva, M., Garazha, A., Poddubskaya, E., et al. (2023) · Cells · doi:10.3390/cells12162022 · Cited by 14
“Several groups of putative response factors are discussed in the literature, including a proteomic spectra of blood serum samples [30], tumor mRNA expression biomarkers [31], transcriptome-based deduced activities of intracellular molecular pathways [32,33], EGFR expression level in tumors, and activating mutations of…”
BackgroundSelf-citation
Metadata
- Authors
- Zhu, Q., Izumchenko, E., Aliper, A. M., Makarev, E., Paz, K., Buzdin, A. A., Zhavoronkov, A. A., & Sidransky, D.
- Venue
- Human Genome Variation
- Published
- 2015-04-02
- Volume
- 2
- Issue
- 1
- Pages
- 15009-15009
- ISSN
- 2054-345X (ISSN-L)
- OpenAlex
- W2327974592
- Cited by
- 50
- References
- 10
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. https://app.cochat.ai/papers/10.1038/hgv.2015.9
- The paper
- Zhu, Q., Izumchenko, E., Aliper, A. M., Makarev, E., Paz, K., Buzdin, A. A., Zhavoronkov, A. A., & Sidransky, D. (2015). Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. Human Genome Variation. https://doi.org/10.1038/hgv.2015.9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.